Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients
This study explored circulating miRNAs and target genes associated with metabolic syndrome (MetS) and cardiometabolic risk in obese patients. Small-RNA sequencing was used to assess the peripheral blood miRNome of 12 obese subjects (6 MetS and 6 non-MetS). Differentially expressed miRNAs and target...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/3/1468 |
id |
doaj-f6d4524293314a7ea2b962f43df1c7e5 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alvaro Cerda Adonai Aralim Amaral Raquel de Oliveira Tamiris Invencioni Moraes Aécio Assunção Braga Magda Elizabeth Graciano-Saldarriaga Cristina Moreno Fajardo Thiago Dominguez Crespo Hirata Vivian Bonezi Antony Brayan Campos-Salazar Egidio Lima Dorea Marcia Martins Silveira Bernik Mario Hiroyuki Hirata Rosario Dominguez Crespo Hirata |
spellingShingle |
Alvaro Cerda Adonai Aralim Amaral Raquel de Oliveira Tamiris Invencioni Moraes Aécio Assunção Braga Magda Elizabeth Graciano-Saldarriaga Cristina Moreno Fajardo Thiago Dominguez Crespo Hirata Vivian Bonezi Antony Brayan Campos-Salazar Egidio Lima Dorea Marcia Martins Silveira Bernik Mario Hiroyuki Hirata Rosario Dominguez Crespo Hirata Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients International Journal of Molecular Sciences obesity metabolic syndrome microRNAs miR-155 <i>CEBPB</i> cardiometabolic risk |
author_facet |
Alvaro Cerda Adonai Aralim Amaral Raquel de Oliveira Tamiris Invencioni Moraes Aécio Assunção Braga Magda Elizabeth Graciano-Saldarriaga Cristina Moreno Fajardo Thiago Dominguez Crespo Hirata Vivian Bonezi Antony Brayan Campos-Salazar Egidio Lima Dorea Marcia Martins Silveira Bernik Mario Hiroyuki Hirata Rosario Dominguez Crespo Hirata |
author_sort |
Alvaro Cerda |
title |
Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients |
title_short |
Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients |
title_full |
Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients |
title_fullStr |
Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients |
title_full_unstemmed |
Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients |
title_sort |
peripheral blood mirome identified mir-155 as potential biomarker of mets and cardiometabolic risk in obese patients |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-02-01 |
description |
This study explored circulating miRNAs and target genes associated with metabolic syndrome (MetS) and cardiometabolic risk in obese patients. Small-RNA sequencing was used to assess the peripheral blood miRNome of 12 obese subjects (6 MetS and 6 non-MetS). Differentially expressed miRNAs and target genes were further analyzed by qPCR in a larger sample of obese patients (48 MetS and 32 non-MetS). miRNA:mRNA interactions were studied using in silico tools. miRNome analysis identified 10 downregulated miRNAs in MetS compared to non-Met patients (<i>p</i> < 0.05). In silico studies revealed three miRNAs (miR-155, miR-181a, and let-7a) and their predictive targets (CCAAT/enhancer-binding protein beta—<i>CEBPB</i>, KRAS proto-oncogene, GTPase—<i>KRAS</i> and suppressor of cytokine signaling 1—<i>SOCS1</i>) with a potential role in the insulin receptor signaling pathway. miR-155 expression was reduced and <i>CEBPB</i> mRNA levels were increased in MetS patients (<i>p</i> < 0.05), and these effects were correlated with the number of MetS diagnostic criteria (<i>p</i> < 0.05). Increased HOMA-IR (>7.6) was associated with low miR-155 levels, high <i>CEBPB</i> expression, and serum hsCRP (<i>p</i> < 0.05). miR-155 was negatively correlated with <i>CEBPB</i>, HOMA-IR, and plasma fibrinogen, and positively correlated with serum adiponectin (<i>p</i> < 0.05). Downregulation of circulating miR-155 is associated with insulin resistance, poor glycemic control, and increased MetS-related cardiometabolic risk, and these effects are potentially mediated by interaction with <i>CEBPB.</i> |
topic |
obesity metabolic syndrome microRNAs miR-155 <i>CEBPB</i> cardiometabolic risk |
url |
https://www.mdpi.com/1422-0067/22/3/1468 |
work_keys_str_mv |
AT alvarocerda peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT adonaiaralimamaral peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT raqueldeoliveira peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT tamirisinvencionimoraes peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT aecioassuncaobraga peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT magdaelizabethgracianosaldarriaga peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT cristinamorenofajardo peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT thiagodominguezcrespohirata peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT vivianbonezi peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT antonybrayancampossalazar peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT egidiolimadorea peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT marciamartinssilveirabernik peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT mariohiroyukihirata peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients AT rosariodominguezcrespohirata peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients |
_version_ |
1724290464704626688 |
spelling |
doaj-f6d4524293314a7ea2b962f43df1c7e52021-02-03T00:01:02ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-02-01221468146810.3390/ijms22031468Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese PatientsAlvaro Cerda0Adonai Aralim Amaral1Raquel de Oliveira2Tamiris Invencioni Moraes3Aécio Assunção Braga4Magda Elizabeth Graciano-Saldarriaga5Cristina Moreno Fajardo6Thiago Dominguez Crespo Hirata7Vivian Bonezi8Antony Brayan Campos-Salazar9Egidio Lima Dorea10Marcia Martins Silveira Bernik11Mario Hiroyuki Hirata12Rosario Dominguez Crespo Hirata13Center of Excellence in Translational Medicine, CEMT-BIOREN & Department of Basic Sciences, Universidad de La Frontera, Av. Alemania 0458, Temuco 4810296, ChileDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilUniversity Hospital, University of Sao Paulo, Av. Prof. Lineu Prestes 2565, Sao Paulo 05508-000, BrazilUniversity Hospital, University of Sao Paulo, Av. Prof. Lineu Prestes 2565, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilThis study explored circulating miRNAs and target genes associated with metabolic syndrome (MetS) and cardiometabolic risk in obese patients. Small-RNA sequencing was used to assess the peripheral blood miRNome of 12 obese subjects (6 MetS and 6 non-MetS). Differentially expressed miRNAs and target genes were further analyzed by qPCR in a larger sample of obese patients (48 MetS and 32 non-MetS). miRNA:mRNA interactions were studied using in silico tools. miRNome analysis identified 10 downregulated miRNAs in MetS compared to non-Met patients (<i>p</i> < 0.05). In silico studies revealed three miRNAs (miR-155, miR-181a, and let-7a) and their predictive targets (CCAAT/enhancer-binding protein beta—<i>CEBPB</i>, KRAS proto-oncogene, GTPase—<i>KRAS</i> and suppressor of cytokine signaling 1—<i>SOCS1</i>) with a potential role in the insulin receptor signaling pathway. miR-155 expression was reduced and <i>CEBPB</i> mRNA levels were increased in MetS patients (<i>p</i> < 0.05), and these effects were correlated with the number of MetS diagnostic criteria (<i>p</i> < 0.05). Increased HOMA-IR (>7.6) was associated with low miR-155 levels, high <i>CEBPB</i> expression, and serum hsCRP (<i>p</i> < 0.05). miR-155 was negatively correlated with <i>CEBPB</i>, HOMA-IR, and plasma fibrinogen, and positively correlated with serum adiponectin (<i>p</i> < 0.05). Downregulation of circulating miR-155 is associated with insulin resistance, poor glycemic control, and increased MetS-related cardiometabolic risk, and these effects are potentially mediated by interaction with <i>CEBPB.</i>https://www.mdpi.com/1422-0067/22/3/1468obesitymetabolic syndromemicroRNAsmiR-155<i>CEBPB</i>cardiometabolic risk |